BrightEdge Ventures

BrightEdge is the innovation and impact investment arm of the American Cancer Society (ACS), founded in 2018 and based in Kennesaw, Georgia. A donor-funded philanthropic impact fund, BrightEdge invests in for-profit, early-stage companies developing cancer-focused therapeutics, diagnostics, medical devices, and enabling technologies. Through the end of 2024, the fund has deployed $52 million across 22 companies, with 15 active portfolio companies holding potential to impact 13.4 million patients. The fund invests globally — across the United States, Canada, Europe, and Asia-Pacific. Investments are aligned with ten American Cancer Society mission priority areas, including cancer health equity, patient survivorship, disease prevention, clinical trial accessibility, and care quality. Recent portfolio companies include Signify Bio (in vivo therapeutics, 2024). BrightEdge also runs the BrightEdge Entrepreneurs program to support founders navigating the early stages of cancer innovation. Managing Director Alice Pomponio brings experience from Red Sky Partners and teaches biomedical innovation at MIT; Director of Investments Lucas de Breed leads deal sourcing and execution. BrightEdge distinguishes itself from pure financial investors by reinvesting all financial returns back into the American Cancer Society's scientific and patient advocacy programs, making every exit outcome directly compound the mission. The fund operates with a dual mandate: achieving genuine venture returns while ensuring the ACS remains a financially self-sustaining engine for cancer research for decades ahead.